Aligos Therapeutics, Inc.
ALGSAligos Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for liver diseases and viral infections.
Earnings
Next report
Nov 5, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Aligos Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for liver diseases and viral infections. The company leverages its expertise in medicinal chemistry to address unmet medical needs in chronic hepatitis B (HBV), metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronaviruses. Its core value proposition lies in developing potentially best-in-class drug candidates that optimize pharmacological properties compared to current standards of care.
A clinical-stage developer targeting best-in-class status through superior potency and selectivity in liver and viral disease indications.
FAQ
- What is Aligos Therapeutics, Inc.'s market cap?
- Aligos Therapeutics, Inc. (ALGS) has a market capitalization of $31.5M and trades on NASDAQ.
- Who are Aligos Therapeutics, Inc.'s competitors?
- Aligos Therapeutics, Inc.'s key competitors include Gilead Sciences, Inc., Assembly Biosciences Inc., Madrigal Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.
- Who does Aligos Therapeutics, Inc. partner with?
- Aligos Therapeutics, Inc.'s notable partners include Emory University, KU Leuven, Xiamen Amoytop Biotech Co., Ltd., and others.
- Where is Aligos Therapeutics, Inc. headquartered?
- Aligos Therapeutics, Inc. is headquartered in United States of America and employs approximately 67 people. It has been publicly traded since 2020.